- Home
- NLSP vs ATNF Comparison
NLSP vs ATNF Comparison
Compare NLSP & ATNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- ATNF
- Stock Information
- Founded
- NLSP 2015
- ATNF 2016
- Country
- NLSP Switzerland
- ATNF United States
- Employees
- NLSP N/A
- ATNF N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- ATNF Biotechnology: Pharmaceutical Preparations
- Sector
- NLSP Health Care
- ATNF Health Care
- Exchange
- NLSP Nasdaq
- ATNF Nasdaq
- Market Cap
- NLSP 6.2M
- ATNF 5.7M
- IPO Year
- NLSP 2021
- ATNF N/A
- Fundamental
- Price
- NLSP $1.81
- ATNF $1.44
- Analyst Decision
- NLSP
- ATNF
- Analyst Count
- NLSP 0
- ATNF 0
- Target Price
- NLSP N/A
- ATNF N/A
- AVG Volume (30 Days)
- NLSP 2.2M
- ATNF 1.1M
- Earning Date
- NLSP 10-18-2024
- ATNF 02-13-2025
- Dividend Yield
- NLSP N/A
- ATNF N/A
- EPS Growth
- NLSP N/A
- ATNF N/A
- EPS
- NLSP N/A
- ATNF N/A
- Revenue
- NLSP N/A
- ATNF N/A
- Revenue This Year
- NLSP N/A
- ATNF N/A
- Revenue Next Year
- NLSP N/A
- ATNF $54.15
- P/E Ratio
- NLSP N/A
- ATNF N/A
- Revenue Growth
- NLSP N/A
- ATNF N/A
- 52 Week Low
- NLSP $1.73
- ATNF $1.16
- 52 Week High
- NLSP $20.80
- ATNF $17.75
- Technical
- Relative Strength Index (RSI)
- NLSP 40.38
- ATNF 39.69
- Support Level
- NLSP $1.87
- ATNF $1.43
- Resistance Level
- NLSP $2.08
- ATNF $1.67
- Average True Range (ATR)
- NLSP 0.20
- ATNF 0.13
- MACD
- NLSP 0.01
- ATNF 0.00
- Stochastic Oscillator
- NLSP 2.33
- ATNF 21.82
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.